• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Liang Yuying

    1/30/25 4:05:21 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ISPC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Liang Yuying

    (Last) (First) (Middle)
    C/O ISPECIMEN INC.
    8 CABOT ROAD, SUITE 1800

    (Street)
    WOBURN MA 01801

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/13/2024
    3. Issuer Name and Ticker or Trading Symbol
    iSpecimen Inc. [ ISPC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Yuying Liang 01/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ISPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISPC

    DatePrice TargetRatingAnalyst
    1/4/2022$20.00Buy
    Craig-Hallum
    11/22/2021$10.00 → $12.00Buy
    EF Hutton
    More analyst ratings

    $ISPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig-Hallum initiated coverage on iSpecimen with a new price target

      Craig-Hallum initiated coverage of iSpecimen with a rating of Buy and set a new price target of $20.00

      1/4/22 7:34:53 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EF Hutton reiterated coverage on iSpecimen with a new price target

      EF Hutton reiterated coverage of iSpecimen with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      11/22/21 11:51:50 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ISPC
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by iSpecimen Inc.

      S-1/A - iSpecimen Inc. (0001558569) (Filer)

      6/11/25 4:30:38 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - iSpecimen Inc. (0001558569) (Filer)

      6/5/25 4:30:43 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form S-1/A filed by iSpecimen Inc.

      S-1/A - iSpecimen Inc. (0001558569) (Filer)

      5/23/25 2:59:52 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ISPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Liang Yuying

      3 - iSpecimen Inc. (0001558569) (Issuer)

      1/30/25 4:05:21 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 3 filed by new insider Lim Robert Bradley

      3 - iSpecimen Inc. (0001558569) (Issuer)

      12/13/24 6:30:47 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 3 filed by new insider Dhaliwal Avtar

      3 - iSpecimen Inc. (0001558569) (Issuer)

      9/30/24 6:01:18 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ISPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually

      WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments. The expanded inventory includes highly sought-after cancer samples across a variety of tumor types, stages, and patient demographics, enabling researchers to access the specific samples they need efficiently and by cancer type, includi

      11/7/24 7:30:00 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • iSpecimen Reports Third Quarter 2024 Results

      LEXINGTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2024. "The third quarter was a period of continued strategic transformation for iSpecimen, primarily driven by several key initiatives," said Tracy Curley, CEO of iSpecimen. "First, we completed a 1-for-20 reverse stock split which helped the Company maintain its Nasdaq listing. Additionally, we secured a $1,000,000 loan facili

      11/7/24 7:00:00 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

      WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of approximately $5 million of the Company's common stock and pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and

      10/31/24 3:07:30 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ISPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

      SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

      2/13/24 5:17:07 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D filed by iSpecimen Inc.

      SC 13D - iSpecimen Inc. (0001558569) (Subject)

      4/17/23 1:27:18 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

      SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

      2/13/23 4:04:55 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ISPC
    Leadership Updates

    Live Leadership Updates

    See more
    • iSpecimen Appoints Eric Langlois as Chief Revenue Officer

      LEXINGTON, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that it appointed Eric Langlois as Chief Revenue Officer, effective immediately. Mr. Langlois previously served as the Company's Senior Vice President of Sales and Business Development. In this new role, Mr. Langlois will manage a restructured commercial team aimed at executing on Company initiatives to better align customer needs, streamline collaboration, support innovation and productivity necessary for driving sca

      1/24/23 7:30:00 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • iSpecimen Names Tracy Curley as Chief Executive Officer

      LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that its Board of Directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately. "I am grateful to the Board and the entire team at iSpecimen for their support over the past four months, and for the confidence they have shown in my ability to lead the Company," said Tracy Curley, CEO of iSpecimen. "The progress we've made this year in terms of operational and financial execution is encouragi

      1/10/23 1:11:01 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • iSpecimen Appoints Joseph J. Basile to Board of Directors

      LEXINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Joseph J. Basile to iSpecimen's Board of Directors (the "Board"), as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022. Mr. Basile is replacing Margaret H. Lawrence as an independent director. Mr. Basile is a sought-after strategic advisor, an accomplished business leader, a skilled negotiator, a trained mediato

      12/5/22 7:30:00 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ISPC
    Financials

    Live finance-specific insights

    See more
    • iSpecimen Reports Second Quarter 2024 Results

      Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024. "iSpecimen's strong results reflect the progress we have made towards operational improvements throughout the Company this year, resulting in a 76% increase in revenue to $2.86 million for

      8/6/24 7:30:00 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

      LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Second Quarter 2024 Results Conference Call  Date:Tuesday, August 6, 2024  Time:8:30 a.m. Eastern Time  Live Call:+1-800-717-1738

      7/25/24 4:05:00 PM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • iSpecimen Reports First Quarter 2024 Results

      LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. "iSpecimen made tremendous progress during the first quarter advancing our most promising operational initiative, Next Day Quotes, a program that expedites the biospecimen transaction process, which has helped elevate our market position and is expected to contribute meaningfully to our growth in 2024 and beyond," said Tracy Curley, C

      5/7/24 7:30:00 AM ET
      $ISPC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care